Companies › IR INNOVATE RESEARCH PRIVATE
1 active drug program in 2 registered trials: 2 Phase 4; Immunology, Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Adapalene Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 4 | Acne; Viral Warts | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07016360 | Adapalene | Phase 4 | Viral Warts | Infectious disease | Feb 2026 |
| NCT07918001 | Adapalene | Phase 4 | Acne | Immunology | Feb 2027 |
Shanghai Longwood Biopharmaceuticals Laboratorio Farmaceutico SIT srl Fujian Mindong Rejuvenation Pharmaceutical Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Eurofarma Laboratorios
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.